MYX
$207M—
Mayne Pharma Group
Specialty pharmaceuticals
Specialty pharma focused on dermatology and women's health in the US market
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$207M
Burn Rate
—
Shares Outstanding
81M
Pipeline Assets
3
Latest Insight(1)
31 Mar 2026substantial_holderCeasing to be a substantial holder
Ceased·Citigroup Global Markets Australia Pty Limited
3M Price
MYX.ASX$2.550-13.0% 3M
Low $2.130High $2.950
Pipeline Assets (3)
NEXTSTELLISOral contraception (estetrol-based)
ApprovedNUCEIVA (prabotulinumtoxinA)Glabellar lines (cosmetic)
ApprovedGeneric dermatology portfolioAcne, skin conditions
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Substantial Holders (5%+ threshold)
4 noticesCEASEDCitigroup Global Markets Australia Pty Limited and related bodies corporate in the Citi group of companies worldwide
CEASEDCitigroup Global Markets Australia Pty Limited
INITIALCitigroup Global Markets Australia Pty Limited and related bodies corporate in the Citigroup group of companies worldwide
5.08%2026-03-27
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
43 competitor trialsPhase 2+ · Non-ASX
Acne, Skin Conditions43 active trials
8 Ph415 Ph33 Ph2/311 Ph26 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (2)
RHOFADE generic competition entry
UpcomingConfirmedarrow_upwardHigh30 June 2026
US HRT black box warning removal — BIJUVA/IMVEXXY impact
UpcomingExpectedarrow_upwardHigh31 Dec 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| RHOFADE generic competition entry Settlement terms allow competing generics at end of FY2026. Revenue headwind for dermatology segment | commercial milestone | Confirmed | arrow_upwardHigh |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(1)
No active trials